Skip to main content

Advertisement

Table 2 Baseline patient demographic and clinical characteristics

From: Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study

  Abrupt (n= 37) Gradual 1 (n= 39) Gradual 2 (n= 40)
Sex, % female 51 51 50
Race/ethnicity, %    
   White 57 54 53
   Black 32 31 33
   Hispanic 5 13 8
   Asian 5 3 5
Age, mean (± SD) years 41.6 (± 10.2) 41.5 (± 10.4) 40.3 (± 9.1)
BMI, mean (± SD) kg/m2 36.2 (± 9.1) 34.0 (± 6.2) 32.3 (± 4.7)
Diagnosis, %    
   Schizophrenia 57 56 53
   Schizoaffective disorder 43 44 47
Olanzapine dose, mean (± SD) mg/day 14.4 (± 5.4) 15.5 (± 6.3) 16.4 (± 7.9)